Compare Ginkgo Bioworks Holdings Inc (DNA) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 5.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| DNA | SJNK | |
|---|---|---|
Market Cap | $763.64M | $4.35B |
Volume | 3,204,177 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $15.83 | $25.57 |
52-Week Low | $5.48 | $24.13 |
Typical Hold Time | 7 Days | 41 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.20, down 0.21% with a bearish technical outlook. The ETF shows strong institutional interest despite recent selling activity by some firms. Dividend distributions remain consistent with recent payments of $0.14-$0.15 per share, providing income appeal in a rising rate environment.
The ETF faces headwinds from technical weakness but maintains income appeal through consistent dividends. Key risks include interest rate sensitivity and institutional selling pressure, while the current yield advantage over Treasuries presents opportunity for income-focused investors in the high-yield bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
